These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 24389907)

  • 1. Pharmacokinetics and pharmacodynamics of ASKP1240, a fully human anti-CD40 antibody, in normal and renal transplanted Cynomolgus monkeys.
    Ma A; Dun H; Song L; Hu Y; Zeng L; Bai J; Zhang G; Kinugasa F; Miyao Y; Sakuma S; Okimura K; Kasai N; Daloze P; Chen H
    Transplantation; 2014 Feb; 97(4):397-404. PubMed ID: 24389907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 1, randomized ascending single-dose study of antagonist anti-human CD40 ASKP1240 in healthy subjects.
    Goldwater R; Keirns J; Blahunka P; First R; Sawamoto T; Zhang W; Kowalski D; Kaibara A; Holman J
    Am J Transplant; 2013 Apr; 13(4):1040-1046. PubMed ID: 23356210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of ASKP1240, a fully human antibody targeting human CD40 with potent immunosuppressive effects.
    Okimura K; Maeta K; Kobayashi N; Goto M; Kano N; Ishihara T; Ishikawa T; Tsumura H; Ueno A; Miyao Y; Sakuma S; Kinugasa F; Takahashi N; Miura T
    Am J Transplant; 2014 Jun; 14(6):1290-9. PubMed ID: 24731050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of ASKP1240 combined with tacrolimus or mycophenolate mofetil on renal allograft survival in Cynomolgus monkeys.
    Song L; Ma A; Dun H; Hu Y; Zeng L; Bai J; Zhang G; Kinugasa F; Sudo Y; Miyao Y; Okimura K; Miura T; Daloze P; Chen H
    Transplantation; 2014 Aug; 98(3):267-76. PubMed ID: 24992357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ASKP1240, a fully human anti-CD40 monoclonal antibody, prolongs pancreatic islet allograft survival in nonhuman primates.
    Watanabe M; Yamashita K; Suzuki T; Kamachi H; Kuraya D; Koshizuka Y; Ogura M; Yoshida T; Aoyagi T; Fukumori D; Shimamura T; Okimura K; Maeta K; Miura T; Sakai F; Todo S
    Am J Transplant; 2013 Aug; 13(8):1976-88. PubMed ID: 23841873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term hepatic allograft acceptance based on CD40 blockade by ASKP1240 in nonhuman primates.
    Oura T; Yamashita K; Suzuki T; Fukumori D; Watanabe M; Hirokata G; Wakayama K; Taniguchi M; Shimamura T; Miura T; Okimura K; Maeta K; Haga H; Kubota K; Shimizu A; Sakai F; Furukawa H; Todo S
    Am J Transplant; 2012 Jul; 12(7):1740-54. PubMed ID: 22420525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics/dynamics of 5c8, a monoclonal antibody to CD154 (CD40 ligand) suppression of an immune response in monkeys.
    Gobburu JV; Tenhoor C; Rogge MC; Frazier DE; Thomas D; Benjamin C; Hess DM; Jusko WJ
    J Pharmacol Exp Ther; 1998 Aug; 286(2):925-30. PubMed ID: 9694951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, phase 1b study of the pharmacokinetics, pharmacodynamics, safety, and tolerability of bleselumab, a fully human, anti-CD40 monoclonal antibody, in kidney transplantation.
    Vincenti F; Klintmalm G; Yang H; Ram Peddi V; Blahunka P; Conkle A; Santos V; Holman J
    Am J Transplant; 2020 Jan; 20(1):172-180. PubMed ID: 31397943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates.
    Kelley SK; Gelzleichter T; Xie D; Lee WP; Darbonne WC; Qureshi F; Kissler K; Oflazoglu E; Grewal IS
    Br J Pharmacol; 2006 Aug; 148(8):1116-23. PubMed ID: 16847437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of pharmacodynamic activity, pharmacokinetics, and anti-product antibody responses to anti-IL-21R antibody therapeutics following IV administration to cynomolgus monkeys.
    Vugmeyster Y; Allen S; Szklut P; Bree A; Ryan M; Ma M; Spaulding V; Young D; Guay H; Bloom L; Leach MW; O'Toole M; Adkins K
    J Transl Med; 2010 Apr; 8():41. PubMed ID: 20420683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys: induction and maintenance therapy.
    Aoyagi T; Yamashita K; Suzuki T; Uno M; Goto R; Taniguchi M; Shimamura T; Takahashi N; Miura T; Okimura K; Itoh T; Shimizu A; Furukawa H; Todo S
    Am J Transplant; 2009 Aug; 9(8):1732-41. PubMed ID: 19519810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose.
    de Vries Schultink AHM; Doornbos RP; Bakker ABH; Bol K; Throsby M; Geuijen C; Maussang D; Schellens JHM; Beijnen JH; Huitema ADR
    Invest New Drugs; 2018 Dec; 36(6):1006-1015. PubMed ID: 29728897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Death receptor 5 agonistic antibody PRO95780: preclinical pharmacokinetics and concentration-effect relationship support clinical dose and regimen selection.
    Xiang H; Reyes AE; Eppler S; Kelley S; Damico-Beyer LA
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):405-15. PubMed ID: 23771513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases.
    Albach FN; Wagner F; Hüser A; Igel J; Joseph D; Hilbert J; Schoelch C; Padula SJ; Steffgen J
    Eur J Clin Pharmacol; 2018 Feb; 74(2):161-169. PubMed ID: 29127458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modification of the Fc Region of a Human Anti-oncostatin M Monoclonal Antibody for Higher Affinity to FcRn Receptor and Extension of Half-life in Cynomolgus Monkeys.
    Nnane IP; Han C; Jiao Q; Tam SH; Davis HM; Xu Z
    Basic Clin Pharmacol Toxicol; 2017 Jul; 121(1):13-21. PubMed ID: 28132416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of basiliximab in Japanese pediatric renal transplant patients.
    Nagai T; Gotoh Y; Watarai Y; Tajima T; Arai K; Uchida K
    Int J Clin Pharmacol Ther; 2010 Mar; 48(3):214-23. PubMed ID: 20197016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, controlled study of bleselumab (ASKP1240) pharmacokinetics and safety in patients with moderate-to-severe plaque psoriasis.
    Anil Kumar MS; Papp K; Tainaka R; Valluri U; Wang X; Zhu T; Schwabe C
    Biopharm Drug Dispos; 2018 May; 39(5):245-255. PubMed ID: 29679478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody.
    Fu J; Wang F; Dong LH; Zhang J; Deng CL; Wang XL; Xie XY; Zhang J; Deng RX; Zhang LB; Wu H; Feng H; Chen B; Song HF
    Acta Pharmacol Sin; 2017 May; 38(5):710-718. PubMed ID: 28317872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys.
    Benincosa LJ; Chow FS; Tobia LP; Kwok DC; Davis CB; Jusko WJ
    J Pharmacol Exp Ther; 2000 Feb; 292(2):810-6. PubMed ID: 10640322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative determination of humanized monoclonal antibody rhuMAb2H7 in cynomolgus monkey serum using a Generic Immunoglobulin Pharmacokinetic (GRIP) assay.
    Yang J; Ng C; Lowman H; Chestnut R; Schofield C; Sandlund B; Ernst J; Bennett G; Quarmby V
    J Immunol Methods; 2008 Jun; 335(1-2):8-20. PubMed ID: 18402977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.